Deals
For Pfizer, Bigger as One May Be Better Than Smaller With Two
- Investors, analysts say pricing climate favors bigger company
- Pfizer pipeline promising against troubling generic landscape
This article is for subscribers only.
For Pfizer Inc., bigger is still better.
By deciding not to split in two after a lengthy evaluation, the New York-based drugmaker is keeping greater leverage with the health insurers and pharmacy benefit managers that have gained increasing power since it first considered a breakup years ago.